Stoke Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell STOK and other ETFs, options, and stocks.

About STOK

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. 

CEO
Ian Frederick Smith
CEOIan Frederick Smith
Employees
128
Employees128
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
2014
Founded2014
Employees
128
Employees128

STOK Key Statistics

Market cap
1.28B
Market cap1.28B
Price-Earnings ratio
34.58
Price-Earnings ratio34.58
Dividend yield
Dividend yield
Average volume
1.12M
Average volume1.12M
High today
$22.89
High today$22.89
Low today
$21.37
Low today$21.37
Open price
$22.69
Open price$22.69
Volume
1.34M
Volume1.34M
52 Week high
$38.69
52 Week high$38.69
52 Week low
$5.35
52 Week low$5.35

Stock Snapshot

Stoke Therapeutics(STOK) stock is priced at $22.47, giving the company a market capitalization of 1.28B. It carries a P/E multiple of 34.58.

As of 2025-11-06, Stoke Therapeutics(STOK) stock has fluctuated between $21.37 and $22.89. The current price stands at $22.47, placing the stock +5.1% above today's low and -1.8% off the high.

The Stoke Therapeutics(STOK)'s current trading volume is 1.34M, compared to an average daily volume of 1.12M.

In the last year, Stoke Therapeutics(STOK) shares hit a 52-week high of $38.69 and a 52-week low of $5.35.

In the last year, Stoke Therapeutics(STOK) shares hit a 52-week high of $38.69 and a 52-week low of $5.35.

STOK News

TipRanks 2d
Stoke Therapeutics reports Q3 EPS (65c), consensus (57c)

Reports Q3 revenue $10.6M, consensus $5.51M. “Stoke’s progress in 2025 has the Company on an important growth trajectory. We are creating an understanding of th...

Simply Wall St 5d
Stoke Therapeutics Is Down 6.9% After New Phase 3 Dravet Syndrome Trial Results - What's Changed

Stoke Therapeutics recently announced new results from the ongoing Phase 3 EMPEROR study of zorevunersen (STK-001), its experimental treatment for Dravet Syndro...

Stoke Therapeutics Is Down 6.9% After New Phase 3 Dravet Syndrome Trial Results - What's Changed

Analyst ratings

91%

of 11 ratings
Buy
90.9%
Hold
9.1%
Sell
0%

People also own

Based on the portfolios of people who own STOK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.